1999
DOI: 10.1006/jmcc.1999.0936
|View full text |Cite
|
Sign up to set email alerts
|

Pyridoxal 5′-Phosphate is an ATP-Receptor Antagonist in Freshly Isolated Rat Cardiomyocytes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
27
0

Year Published

2008
2008
2019
2019

Publication Types

Select...
4
3

Relationship

1
6

Authors

Journals

citations
Cited by 29 publications
(30 citation statements)
references
References 3 publications
3
27
0
Order By: Relevance
“…However, the ATP-induced increases in [Ca 2ϩ ] i were almost completely abolished in cells incubated in Px, indicating that Px is a viable P2 receptor antagonist in murine neuronal cells. This finding is consistent with similar studies in both neuronal cells and in isolated cardiomyocytes (29,43,60), but to our knowledge, this novel finding is the first demonstration in isolated DRG neurons, which are of particular relevance to the EPR.…”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…However, the ATP-induced increases in [Ca 2ϩ ] i were almost completely abolished in cells incubated in Px, indicating that Px is a viable P2 receptor antagonist in murine neuronal cells. This finding is consistent with similar studies in both neuronal cells and in isolated cardiomyocytes (29,43,60), but to our knowledge, this novel finding is the first demonstration in isolated DRG neurons, which are of particular relevance to the EPR.…”
Section: Discussionsupporting
confidence: 93%
“…Px, the chemical precursor of PLP, is a nonselective P2 receptor antagonist (43,51,60) and can be safely administered to humans (24,55). Venous samples were collected to measure plasma PLP, lactate (Accutrend Lactate; Mannheim, Germany), serum potassium (EasyElectrolyte Analyzer; Medica, Bedford, MA), and pH (Accumet Basic AB15; Cole-Parmer, Vernon Hills, IL).…”
Section: In Vivo Human Protocolmentioning
confidence: 99%
“…In view of the therapeutic potential of PLP for the prevention of ischemic heart disease [ 37 ], it seems appropriate to review the evidence for the action of PLP at the purinergic receptors in the myocardium. By using an isolated perfused heart, an extensive study was undertaken to examine if the positive inotropic effect of ATP was attenuated by PLP [ 58 ]. It was observed that the time-dependent increases in LVDP, + dP/ dt, and -dP/dt by ATP were prevented by pretreatment with PLP.…”
Section: Mechanisms Of Plp Action In the Ischemic Heart Diseasementioning
confidence: 99%
“…Pyridoxal phosphate had an effect at concentrations equal to those of α, β-methylATP. Wang et al (1999) found that pyridoxal phosphate was an ATP receptor antagonist in rat cardiomyocytes. Binding of 10 μΜ ATP-S to low affinity binding sites was significantly reduced by 1 μΜ pyridoxal phosphate.…”
Section: Pyridoxal Phosphate and Purinoceptorsmentioning
confidence: 99%
“…Binding of 10 μΜ ATP-S to low affinity binding sites was significantly reduced by 1 μΜ pyridoxal phosphate. Wang et al (1999) concluded that since normal plasma concentrations of pyridoxal phosphate range from 24 to 81 nM, pyridoxal phosphate probably would not function as an inhibitor under physiological conditions. However, they also noted that the higher ATP concentrations that were needed in the intact heart and cardiomyocytes than in the sarcolemmal membranes might result from ATP hydrolysis thus suggesting that the effective concentration of ATP might be lower than the administered amount.…”
Section: Pyridoxal Phosphate and Purinoceptorsmentioning
confidence: 99%